Why the study?
Can microarray-based gene expression signatures reliably differentiate between ischemic and nonischemic etiologies in end-stage human heart failure?
Population
279 end-stage human heart failure samples from one cDNA and two publicly available high-density…
Comparison
Microarray-based gene expression profiling using… vs Ischemic versus Nonischemic cardiomyopathies
Design
Other
Authors
Loading...
Microarray signatures cannot reliably differentiate ICM from NICM; leaves open whether refined transcriptomic approaches can achieve clinical utility.
Can microarray-based gene expression signatures reliably differentiate between ischemic and nonischemic etiologies in end-stage human heart failure?
Microarray-based transcriptomic signatures show poor separation between ischemic and nonischemic end-stage heart failure, though distinct biological pathways are overrepresented in each etiology.
Kuner et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: